Propanc’s PRP Shows 90% Tumor Growth Inhibition in Pancreatic Cancer Models, Targeting Untapped Biology
Event summary
- Propanc Biopharma reported preclinical data showing >90% tumor growth inhibition with PRP in pancreatic cancer models, contrasting with Revolution Medicines’ approved daraxonrasib.
- PRP demonstrated >2.5-fold median survival extension, reduced metastatic burden, and tumor microenvironment remodeling in PDAC models.
- Propanc plans to initiate a Phase 1b first-in-human study of PRP in Q1 2027 across Australia for advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers.
- PRP holds FDA Orphan Drug Designation for pancreatic cancer and is not restricted to RAS genotype, unlike daraxonrasib.
The big picture
Propanc’s PRP represents a novel approach to pancreatic cancer treatment, addressing limitations of existing RAS-targeted therapies by focusing on tumor microenvironment remodeling and metastatic suppression. The upcoming Phase 1b study will be critical in validating PRP’s potential as a combination or sequential therapy in a disease with high unmet need. The contrast with Revolution Medicines’ daraxonrasib highlights the strategic opportunity to target complementary biological pathways in PDAC.
What we're watching
- Combination Strategy
- Whether PRP can establish itself as a complementary therapy to RAS inhibitors like daraxonrasib, targeting untapped biology in pancreatic cancer.
- Clinical Translation
- The pace at which preclinical efficacy translates into human outcomes in the upcoming Phase 1b study.
- Regulatory Pathway
- How Propanc navigates the Orphan Drug Designation status to accelerate PRP’s development and potential approval.
